Premium
Simultaneous analysis of haloperidol, its three metabolites and two other butyrophenone‐type neuroleptics by high performance liquid chromatography with dual ultraviolet detection
Author(s) -
Higashi Yasuhiko,
Kitahara Miyuki,
Fujii Youichi
Publication year - 2006
Publication title -
biomedical chromatography
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.4
H-Index - 65
eISSN - 1099-0801
pISSN - 0269-3879
DOI - 10.1002/bmc.547
Subject(s) - chemistry , chromatography , high performance liquid chromatography , butyrophenone , haloperidol , detection limit , dopamine , neuroscience , biology
We investigated simultaneous determination of haloperidol (HAL), its three metabolites [reduced HAL (R‐HAL), 3‐(4‐fluorobenzoyl)propionic acid (FBPA) and 4‐(4‐chlorophenyl)‐4‐hydroxypiperidine (CPHP)] and two related compounds [spiperone (SPI) and droperidol (DRO)] in phosphate‐buffered saline using high‐performance liquid chromatography (HPLC) coupled with dual ultraviolet detection (220 and 250 nm). Retention times of HAL, R‐HAL, FBPA, CPHP, SPI and DRO were 16.8, 11.8, 10.2, 4.1, 12.6 and 8.3 min, respectively. Their lower limits of detection were 7.5, 14, 4.5, 12, 10 and 20 ng/mL in the same order. The coefficients of variation for their intra‐ and inter‐day assays were less than 7.8 and 9.4%, respectively. Of the other centrally acting drugs, only amoxapine interfered with the peak of DRO. Using our procedure, the binding study of tested compounds to synthetic melanin, human serum albumin and α 1 ‐acid glycoprotein was performed by determining the unbound concentration to total concentration ratio. These results indicated that simultaneous assay of HAL, R‐HAL, FBPA, CPHP, SPI and DRO in phosphate‐buffered saline by HPLC equipped with dual ultraviolet detection is simple, sensitive and reproducible. Also, our assay system can be applied to the binding study of these compounds to synthetic melanin, human serum albumin and α 1 ‐acid glycoprotein. Copyright © 2005 John Wiley & Sons, Ltd.